BriaCell Therapeutics Corp. (OTCMKTS:BCTXF) Logo

The stock of BRIACELL THERAPEUTICS CORP COMMON SHARE (OTCMKTS:BCTXF) registered an increase of 23100% in short interest. BCTXF’s total short interest was 69,600 shares in December as published by FINRA. Its up 23100% from 300 shares, reported previously. With 30,800 shares average volume, it will take short sellers 2 days to cover their BCTXF’s short positions.

It closed at $0.0781 lastly. It is down 0.00% since December 6, 2017 and is . It has underperformed by 15.62% the S&P500.

BriaCell Therapeutics Corp., a biotechnology company, engages in the research and development of cancer immunotherapy technology in Canada. The company has market cap of $12.35 million. It is involved in developing BriaVax, a genetically engineered whole-cell vaccine that is in Phase I/IIa clinical trial to treat advanced breast cancer, as well as other cancers comprising prostate, ovarian, pancreas, lung, and bladder cancers; and BriaDx, a companion diagnostic test for BriaVax. It currently has negative earnings.

Another recent and important BriaCell Therapeutics Corp. (OTCMKTS:BCTXF) news was published by Investingnews.com which published an article titled: “New to the Investing News Network – Investing News Network” on November 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.